scPharmaceuticals Inc. (SCPH): Price to Earnings Adjusted for Growth Rate
The PEG growth potential ratio illustrates the valuation dynamics of scPharmaceuticals Inc. (SCPH), where 0.00 represents the latest metric level. The company is implementing the Furoscix system for home heart failure therapy to reduce hospital expenditures. Management is focusing on engagement with insurers to commercialize the product. The stability of medical technology supplies in the US is ensured by diversified chains and strategic warehouse reserves.
Metric breakdowns and analytics for scPharmaceuticals Inc. (SCPH)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- shareholders' equity book value data:
- business debt structure and liquidity details:
Debt to Capital scPharmaceuticals Inc.|SCPH - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital scpharmaceuticals.com|SCPH - Company Debts|Debts to Net Assets scPharma|SCPH - Company Long-Term Debts|Company Current Liabilities scPharmaceuticals|Critical Liquidity Ratio scpharmaceuticals.com
- earnings and market ratios statistics:
SCPH - Net Profit|Expected Net Income scPharmaceuticals Inc.|SCPH - P/E Multiple|Forward P/E Multiple scpharmaceuticals.com|SCPH - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation scPharma|SCPH - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months scPharmaceuticals|SCPH - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth scpharmaceuticals.com|SCPH - Earnings growth in current year|Expected earnings per share growth for next year scPharmaceuticals Inc.
Fundamental company analysis:SCPH, scPharmaceuticals, Inc.
The PEG ratio compares the market value of earnings to their expansion rate, where a value below one signals a fundamental undervaluation of the asset. The current peg_co metric at 0.00 reflects the balance between the share price and growth dynamics, which for scPharmaceuticals Inc. (SCPH) is supported by the expansion of its cardiology specialist staff while maintaining a stable core of R&D engineers.
Competing companies
HLN (Haleon PLC) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Kenvue Corp KVUE|Verona Pharma Inc. (VRNA) - Price to Earnings Adjusted for Growth Rate|MENS: Price/Earnings to Growth Multiple|ligand.com - Company Value to Earnings Growth Ratio|AMRX: PEG Multiple|Perrigo Company PLC - Growth-Adjusted Payback Ratio|ALVO (Alvotech Corp) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Liquidia Inc. LQDA|Price/Earnings to Growth Ratio Galapagos NV (GLPG)|ANIP (anipharmaceuticals.com) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio MannKind MNKD|Growth-Adjusted Market Cap to Net Income Amphastar Pharmaceuticals Inc (AMPH)|Pacira - PEG Multiple|ARS Corp (SPRY) - Price/Earnings to Growth Multiple|Theravance Biopharma (TBPH) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio AQST (aquestive.com)|TECX (Tectonic Therapeutic Inc.) - PEG Multiple|TNXP: Growth-Adjusted Payback Ratio|PEG Multiple SXTC|PEG Multiple eupraxiapharma.com (EPRX)|Price/Earnings to Growth Ratio BioHarvest Sciences BHST|Growth-Adjusted Payback Ratio EXOZ|ORMP - Price/Earnings to Growth Ratio|Entera Bio Ltd. (ENTX) - Price/Earnings to Growth Multiple|HYFT: PEG Multiple|ABVC BioPharma, Inc (ABVC) - PEG Multiple|CPIX (Cumberland Pharmaceuticals) - PEG Multiple|Price/Earnings to Growth Multiple quantumbiopharma.com (QNTM)|PEG Multiple FGEN|TELO - Price to Earnings Adjusted for Growth Rate|Rani Therapeutics Holdings, Inc. - Price/Earnings to Growth Multiple|PEG Multiple Synergy CHC Corp. SNYR|RLYB: Price/Earnings to Growth Multiple|Lexaria Bioscience - Company Value to Earnings Growth Ratio|PULM: PEG Multiple|PTHL - Growth-Adjusted Market Cap to Net Income|APM (Aptorum Group Ltd) - PEG Multiple|Price/Earnings to Growth Multiple Lyra Therapeutics Inc (LYRA)|PEG Multiple IBO|PEG Multiple tnfpharma.com (TNFA)|Price/Earnings to Growth Ratio cbdMD YCBD|PainReform Ltd - Price/Earnings to Growth Ratio|CYTO - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Lipella Pharma LIPO|OPTN (OptiNose, Inc.) - Price/Earnings to Growth Multiple|pieris.com - Growth-Adjusted Payback Ratio|PROC (Procaps) - PEG Multiple|Petros Pharmaceuticals Inc (PTPI) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Qilian International Holding Group Limited (QLI)|ACELYRIN Inc. - Growth-Adjusted P/E Ratio|PEG Multiple TFFP (TFF Pharmaceuticals)
